US Stock MarketDetailed Quotes

SGMT Sagimet Biosciences

Watchlist

3.660
+0.160+4.57%

Close Mar 5 16:00 ET

3.640
-0.020-0.55%

Post 16:38 ET

117.83MMarket Cap-3.14P/E (TTM)

Sagimet Biosciences Stock Forum

Lnova

Feb 22 15:11

Presentation Scheduled for Weds 2-26

$Sagimet Biosciences (SGMT.US)$
“SAN MATEO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that an oral presentation on denifanstat's effect on triglycerides and LDL-cholesterol in advanced fibrosis patients will be delivered at the MASH Pathogenesis and Therapeutic Approac...

jingchris8486

Jan 31 14:56

$Sagimet Biosciences (SGMT.US)$ bullish bounce.

liquidityHunter

Jan 6 19:00

$Sagimet Biosciences (SGMT.US)$ how is this not under the radar ?

Jaguar8

Nov 18, 2024 09:47

NEWS PM

$Sagimet Biosciences (SGMT.US)$
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024
Sagimet Biosciences presented Phase 2b data for denifanstat, its fatty acid synthase (FASN) inhibitor, at AASLD 2024. The FASCINATE-2 trial showed significant improvement in liver fibrosis in high-risk MASH patients, particularly in the F3 population where 49% of denifanstat-treated patients showed improvement versus 13% for placebo. AI-ba...

Jaguar8

Nov 12, 2024 05:31

NEWS

$Sagimet Biosciences (SGMT.US)$
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
Ascletis Pharma has completed enrollment of 480 patients in its Phase III clinical trial of ASC40 (denifanstat), a once-daily oral tablet for treating moderate to severe acne. The randomized, double-blind, placebo-controlled trial began on January 24, 2024, with patients divided equally between treatment and placebo groups. The study will evalua...

Trytosaveabit

Oct 29, 2024 06:04

Update

$Sagimet Biosciences (SGMT.US)$ Reuters· 3 mins ago
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions With FDA on the Development of Denifanstat for Mash; Phase 3 Program Initiation Expected by End of 2024

Jaguar8

Oct 11, 2024 06:04

NEWS

$Sagimet Biosciences (SGMT.US)$
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
Sagimet Biosciences Inc. (Nasdaq: SGMT) announced the publication of results from their Phase 2b FASCINATE-2 clinical trial of denifanstat in The Lancet Gastroenterology & Hepatology. The trial, conducted on patients with biopsy-confirmed metabolic-dysfunction associated steatohep...

Trytosaveabit

Oct 1, 2024 14:21

$Sagimet Biosciences (SGMT.US)$ Nice to see a bit of a recovery🤫

Rivera

Oct 1, 2024 07:50

Nice

$Sagimet Biosciences (SGMT.US)$

No comment yet

SGMT Sagimet Biosciences

Sagimet Biosciences Stock Forum

Trending Stocks